Carlos Ciller, Stefanos Apostolopoulos, Sandro De Zanet found RetinAI

Beginning of the development of RetinAI Discovery®, a first in-class data management platform integrated with AI modules

Start of large projects involving RetinAI Discoveryfor Research and Clinical Study support in EU

RetinAI Discovery is CE marked and a master collaboration agreement is signed with Novartis for Discovery Unity & Discovery for Clinical Trials

FDA clearance for RetinAI Discovery and expansion to new disease areas: diabetic retinopathy, diabetic macular edema, glaucoma, geographic atrophy